

**NATIONAL INSTITUTE FOR HEALTH AND CARE
EXCELLENCE**

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

**STA Tafamidis for treating transthyretin amyloid
cardiomyopathy**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Consultation

- | |
|---|
| 1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how? |
|---|

| |
|---|
| The committee acknowledged the equalities issues raised during scoping which related to ATTR-CM disproportionately affecting people from certain ethnic groups. It considered that the equalities issues raised were not something that could be addressed in its recommendations (see ACD section 3.25). |
|---|

- | |
|--|
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these? |
|--|

| |
|-----|
| No. |
|-----|

- | |
|--|
| 3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these? |
|--|

| |
|---|
| During the committee meeting one patient expert highlighted that inconsistent levels of awareness of ATTR-CM, and the type of ATTR-CM a person has, could contribute to variations in diagnosis delays, across individuals and different regions (see ACD section 3.3). The committee recognised that challenges in diagnosing ATTR-CM and inconsistency in |
|---|

awareness of the condition could contribute to regional disparities in diagnosis and access to treatment. However, the agreed that this was not something that could be address in their recommendations.

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No.

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No.

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

No.

7. Have the committee's considerations of equality issues been described in the appraisal consultation document, and, if so, where?

Yes, ACD section 3.25

Approved by Associate Director (name): Jasdeep Hayre

Date: 27/05/2020

Final appraisal determination

(when an ACD issued)

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the committee addressed these?

A statement received during consultation noted that the recommendation would deny older people with ATTR-CM access to tafamidis which could maintain their health and reduce morbidity, while those in EAMS could receive tafamidis. The committee was also aware that evidence suggested ATTR-CM prevalence in women may be underestimated, because women may be less likely to have the red flag symptoms that trigger referral. The committee considered that their recommendations did not disproportionately disadvantage women or certain age groups, and that access to tafamidis through EAMS was not in the scope of their recommendation.

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

Not applicable.

3. If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

Not applicable.

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified

| |
|---|
| in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality? |
| Not applicable. |

| |
|---|
| 5. Have the committee's considerations of equality issues been described in the final appraisal determination, and, if so, where? |
| Yes, see FAD section 3.25. |

Approved by Associate Director (name): Jasdeep Hayre

Date: 28 September 2020